Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from COSMO Pharmaceuticals N.V. ( (CH:COPN) ).
Cosmo Pharmaceuticals has received European Commission approval for Winlevi®, a novel acne treatment, marking a significant milestone for the company. This approval allows Cosmo to expand its market presence in Europe, offering a new, effective topical anti-androgen therapy for acne, which is expected to contribute to the company’s growth and provide a much-needed solution for adolescents and adults suffering from acne vulgaris.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. Founded in 1997 and headquartered in Dublin, Ireland, with branches in the USA and Italy, Cosmo focuses on designing and manufacturing advanced medical solutions to improve the standard of care globally.
Average Trading Volume: 21,428
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.1B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.